Stati Uniti - inglese - NLM (National Library of Medicine)

zhejiang yongtai pharmaceutical co., ltd. - gabapentin (unii: 6cw7f3g59x) (gabapentin - unii:6cw7f3g59x) - gabapentin is indicated for: - management of postherpetic neuralgia in adults - adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as gabapentin, during pregnancy. encourage women who are taking gabapentin during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling the toll free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/ . risk summary there are no adequate data on the developmental risks associated with the use of gabapentin in pregnant women. in nonclinical studies in mice, rats, and rabbits, gabapentin was developmentally toxic (increased fetal skeletal a

Stati Uniti - inglese - NLM (National Library of Medicine)

tianjin kingyork pharmaceuticals co., ltd - methylprednisolone sodium succinate (unii: lec9gky20k) (methylprednisolone - unii:x4w7zr7023) - when oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, usp is indicated as follows: allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions,  serum sickness, transfusion reactions. dermatologic diseases: bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. gastrointestinal diseases: to tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. hematologic disorders: acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamond-blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. miscellaneous: trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. neoplastic diseases: for the palliative management of leukemias and lymphomas. nervous system: acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. ophthalmic diseases: sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. renal diseases: to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. respiratory diseases: berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). for the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. methylprednisolone sodium succinate for injection, usp sterile powder is contraindicated: - in systemic fungal infections and patients with known hypersensitivity to the product and its constituents. the methylprednisolone sodium succinate for injection, usp 40 mg presentation includes lactose monohydrate produced from cow’s milk. this presentation is therefore contraindicated in patients with a known or suspected hypersensitivity to cow’s milk or its components or other dairy products because it may contain trace amounts of milk ingredients. - for intrathecal administration. reports of severe medical events have been associated with this route of administration. intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. additional contraindication for the use of methylprednisolone sodium succinate for injection, usp sterile powder preserved with benzyl alcohol: formulations preserved with benzyl alcohol are contraindicated for use in premature infants. (see warnings and precautions, pediatric use ).

Arabia Saudita - inglese - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

montajat veterinary pharmaceuticals co. ltd., saudi arabia - spray - 70 % - isopropyl alcohol

Arabia Saudita - inglese - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

montajat veterinary pharmaceuticals co. ltd., saudi arabia - spray - 70 % - isopropyl alcohol

Giordania - inglese - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

بيلا للصناعات الدوائية - pella pharmaceuticals co.ltd - eflornithine hydrochloride 13.9 % - 13.9%

Giordania - inglese - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

بيلا للصناعات الدوائية - pella pharmaceuticals co.ltd - erythromycin 4 % - 4%

Stati Uniti - inglese - NLM (National Library of Medicine)

cspc ouyi pharmaceutical co., ltd. - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy

Arabia Saudita - inglese - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

montajat veterinary pharmaceuticals co. ltd., saudi arabia - gel - 0.71 mg - isopropyl alcohol

Arabia Saudita - inglese - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

montajat veterinary pharmaceuticals co. ltd., saudi arabia - gel - 0.71 mg - isopropyl alcohol

Tanzania - inglese - Tanzania Medicinces & Medical Devices Authority

shanghai fosun pharmaceutical industrial development co., ltd, china - sulfadoxine/pyrimethamine/amodiaquine (as hydrochloride) - dispersible tablets - 500/25